P2X7R antagonists in chronic stress-based depression models: a review
Open Access
- 19 July 2021
- journal article
- review article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 271 (7) , 1343-1358
Abstract
Depression affects around 320 million people worldwide. Growing evidence proposes the immune system to be the core interface between psychosocial stress and the neurobiological and behavioural features of depression. Many studies have identified purinergic signalling via the P2X7 receptor (P2X7R) to be of great importance in depression genesis yet only a few have evaluated P2X7R antagonists in chronic stress-based depression models. This review summarizes their findings and analyses their methodology. The four available studies used three to nine weeks of unpredictable, chronic mild stress or unpredictable, chronic stress in male mice or rats. Stress paradigm composition varied moderately, with stimuli being primarily psychophysical rather than psychosocial. Behavioural testing was performed during or after the last week of stress application and resulted in depressive-like behaviours, immune changes (NLRP3 assembly, interleukin-1β level increase, microglia activation) and neuroplasticity impairment. During the second half of each stress paradigm, a P2X7R antagonist (Brilliant Blue G, A-438079, A-804598) was applied. Studies differed with regard to antagonist dosage and application timing. Nonetheless, all treatments attenuated the stress-induced neurobiological changes and depressive-like behaviours. The evidence at hand underpins the importance of P2X7R signalling in chronic stress and depression. However, improvements in study planning and reporting are necessary to minimize experimental bias and increase data purview. To achieve this, we propose adherence to the Research Domain Criteria and the STRANGE framework.Keywords
Funding Information
- Else Kröner-Fresenius-Stiftung (IMPRS TP PhD Residency Program)
- Max-Planck-Gesellschaft (IMPRS-TP Programm (minor funding), IMPRS-TP Programm)
- Bundesministerium für Forschung, Technologie und Raumfahrt (IMADAPT, FKZ: 01KU1901))
- Marie Skłodowska-Curie innovative training network PurinesDX
- Max Planck Institute of Psychiatry
This publication has 179 references indexed in Scilit:
- Microglial Dysregulation in Psychiatric DiseaseJournal of Immunology Research, 2013
- Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responsesPurinergic Signalling, 2013
- The Costs of DepressionPsychiatric Clinics of North America, 2012
- Inhibition of Neuronal Voltage-Gated Sodium Channels by Brilliant Blue GMolecular Pharmacology, 2011
- Identifying and Avoiding Bias in ResearchPlastic and Reconstructive Surgery, 2010
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptorsBritish Journal of Pharmacology, 2009
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major DepressionBiological Psychiatry, 2009
- Population-Based Study of First Onset and Chronicity in Major Depressive DisorderArchives of General Psychiatry, 2008
- Childhood maltreatment predicts adult inflammation in a life-course studyProceedings of the National Academy of Sciences, 2007